{"entity":{"id":"nct05683886","kind":"trial","name":"A Study of KC1036 in Patients with Advanced Thymic Tumors","aka":[],"tldr":"A phase 2 trial of KC1036 in thymoma and thymic carcinoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of KC1036 in Patients with Advanced Thymic Tumors is a phase 2 interventional study registered as NCT05683886 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2023-02-22 and due to reach its primary completion in 2025-02. Interventions recorded: KC1036.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05683886","url":"https://clinicaltrials.gov/study/NCT05683886"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["thymic-epithelial"],"sections":[],"technologies":[],"targets":[],"drugs":["kc1036"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05683886","phase":"2","setting":"A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct05683886/","neighbours":{"cancer":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"}],"drug":[{"id":"kc1036","kind":"drug","name":"KC1036","route":"/drugs/kc1036/"}],"company":[{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/"}]}}